Leadership / Most Powerful Women in Pharma 2022
Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations. The annual…
Address: 345 Park Avenue
New York, New York
10154
Tel: 800-332-2056
Web: http://www.bms.com/pages/default.aspx
Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Bristol-Myers Squibb produces medicines against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
At Bristol-Myers Squibb, its BioPharma strategy combines a major pharma company with a successful biotech company which helps to focus on the customers’ needs giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.
Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations. The annual…
The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing.…
AstraZeneca’s CEO Pascal Soriot warns that the new US legislation controlling drug prices would reduce innovators’ capacity to recover drug development investments and therefore discourage innovation, especially for drugs with smaller…
While patient groups view the United States’ new Inflation Reduction Act as a positive move towards capping out-of-pocket drug costs for older Americans, the innovative pharma industry, after aggressively lobbying…
Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme…
Monica Weldon draws on her own experience as a rare disease patient advocacy group CEO to outline how such groups can work collaboratively with other stakeholders in drug development to…
US generics giant Mallinckrodt, which declared bankruptcy in 2020 after a stream of litigation regarding its role in the opioid epidemic and underpaying Medicaid rebates for its drug Acthar, has…
As of July 1st, long-term Merck alumni, Chirfi Guindo, will be returning to the company to lead Human Health Marketing as chief marketing officer for Merck Human Health and will…
After US life expectancy fell for a second consecutive year, FDA Commissioner, Dr Robert M. Califf, speaking at the recent 2022 Biotechnology Innovation Organization (BIO22) International Convention, discussed what he…
At its recent convention, the first live one in 3 years, the Biotechnology Innovation Organization (BIO) announced the Executive Committee directors for the 2022-2023 term, elected during the event that…
Longtime Director of the Center for Drug Evaluation and Research CDER, Janet Woodcock, will be changing roles at the US Food & Drug Administration (FDA) and moving away from drug…
In the United States, clinical trials have long been criticized for inadequate inclusion of minority patients and consequently for not representing the country’s diverse population. The FDA recently released new…
See our Cookie Privacy Policy Here